Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease

Journal of Rheumatology

Volumn 40, Issue 4, 2013, Pages 484-492

  Cavagna, Lorenzo ^a   Caporali, Roberto ^a   Abdì Alì, Lul ^b   Dore, Roberto ^a   Meloni, Federica ^a   Montecucco, Carlomaurizio ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b IRCCS   (Italy)

Author keywords

Anti Jo1; Antisynthetase syndrome; Corticosteroid refractory; Cyclosporine; Interstitial lung disease

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; JO 1 ANTIBODY; METHOTREXATE; OXYGEN; PREDNISONE;

ADULT; AGED; ANTISYNTHETASE SYNDROME; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPERTENSION; INTERSTITIAL LUNG DISEASE; LONG TERM CARE; LOW DRUG DOSE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LUNG VOLUME; MALE; ONSET AGE; OXYGEN THERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODIES, ANTINUCLEAR; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYOSITIS; PREDNISONE; RESPIRATORY FUNCTION TESTS; RETREATMENT; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84875832150     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121026     Document Type: Article

References (59)

1. Mammen AL. Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Ann NY Acad Sci 2010;1184:134-53.
2. Gomard-Mennesson E, Fabien N, Cordier JF, Ninet J, Tebib J, Rousset H. Clinical significance of anti-histidyl-tRNA synthetase (Jo1) autoantibodies. Ann NY Acad Sci 2007;1109:414-20.
3. Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: An update on clinical and pathophysiological significance. Curr Opin Rheumatol 2007;19:523-9.
4. Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol 2010;22:633-8.
5. Passadore I, Iadarola P, Di Poto C, Giuliano S, Montecucco C, Cavagna L, et al. 2-DE and LC-MS/MS for a comparative proteomic analysis of BALf from subjects with different subsets of inflammatory myopathies. J Proteome Res 2009;8:2331-40.
6. Katzap E, Barilla-LaBarca ML, Marder G. Antisynthetase syndrome. Curr Rheumatol Rep 2011;13:175-81.
7. Hervier B, Devilliers H, Stanciu R, Meyer A, Uzunhan Y, Masseau A, et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 2012;12:210-7.
8. Oddis CV. Current approach to the treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol 2000;12:492-7.
9. Imbert-Masseau A, Hamidou M, Agard C, Grolleau JY, Cherin P. Antisynthetase syndrome. Joint Bone Spine 2003;70:161-8.
10. Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senécal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: Insights into clinical features and outcomes. Arthritis Res Ther 2007;9:R78.
11. Lega JC, Cottin V, Fabien N, Thivolet-Bejui F, Cordier JF. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: A similar condition? J Rheumatol 2010;37:1000-9.
12. Dieval C, Ribeiro E, Merci P, Blanco P, Duffau P, Longy-Boursier M. Antisynthetase syndrome: A retrospective study of 14 patients. Rev Med Interne 2011;33:76-9.
13. Stanciu R, Guiguet M, Musset L, Touitou D, Beigelman C, Rigolet A, et al. Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: Pulmonary involvement predicts disease-modifying antirheumatic drug use. J Rheumatol 2012;39:1835-9.
14. Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005;52:2439-46.
15. Schnabel A, Reuter M, Biederer J, Richter C, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 2003;32:273-84.
16. Joffe MM, Love LA, Left RL, Fraser DD, Targoff IN, Hicks JE, et al. Drugs therapy of the idiopathic inflammatory myopathies: Predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993;94:379-87.
17. Lange U, Piegsa M, Muller-Ladner U, Strunk J. Anti-Jo1 antibody positive polymyositis - Successful therapy with leflunomide. Autoimmunity 2006;39:261-4.
18. Hervier B, Masseau A, Mussini JM, Audrain M, Hamidou MA. Long-term efficacy of mycophenolate mofetil in a case of refractory antisynthetase syndrome. Joint Bone Spine 2009; 76:575-6.
19. Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006;65:974-5.
20. Vandenbroucke E, Grutters JC, Altenburg J, Boersma WG, ter Borg EJ, van den Bosch JM. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int 2009;29:1499-502.
21. Ball EM, Savage EM, Pendleton A. Refractory anti-synthetase syndrome treated with rituximab. Rheumatology 2010;49:1013.
22. Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: A retrospective case series. Rheumatology 2009;48:968-71.
23. Marie I, Dominique S, Janvresse A, Levesque H, Menard JF. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med 2012;106:581-7.
24. Furlan A, Botsios C, Ruffatti A, Todesco S, Punzi L. Anti-synthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptors. Joint Bone Spine 2008;75:366-7.
25. Guglielmi S, Merz TM, Gugger M, Suter C, Nicod LP. Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus. Eur Respir J 2008;31:213-7.
26. Gruhn WA, Diaz-Buxi JA. Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis/polymyositis. J Rheumatol 1987;14:1045-7.
27. Tellus MM, Buchanan RR. Effective treatment of anti Jo-1 antibody-positive polymyositis with cyclosporine. Br J Rheumatol 1995;34:1187-8.
28. Dawson JK, Abernethy VE, Lynch MP. Effective treatment of anti Jo-1 antibody-positive polymyositis with cyclosporin. Br J Rheumatol 1997;36:144-5.
29. Sauty A, Rochat T, Schoch OD, Hamacher J, Kurt AM, Dayer JM, et al. Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies. Eur Resp J 1997;10:2907-12.
30. Koreeda Y, Higashimoto I, Yamamoto M, Takahashi M, Kaji K, Fujimoto M, et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med 2010;49:361-9.
31. American Thoracic Society. Lung function testing: Selection of reference values and interpretative strategies. Am Rev Respir Dis 1991;144:1202-18.
32. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault J-C. Lung volumes and forced ventilator flows. Eur Respir J 1993;6:5-40.
33. Ogilvie CM, Forster RE, Blakemore WS, Morton JW. A standardized breath-holding technique for clinical measurement of the diffusing capacity of the lung for carbon monoxide. J Clin Invest 1957;36:1-7.
34. Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: Correlation with pathologic scoring. AJR Am J Roentgenol 1997;169:977-83.
35. Kocheril SV, Appleton BE, Somers EC, Kazerooni EA, Flaherty KR, Martinez FJ, et al. Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum 2005;53:549-57.
36. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2002;165:227-304.
37. Cavagna L, Fusetti C, Montecucco C, Caporali R. Anticyclic citrullinated peptide antibodies as markers of erosive arthritis in antisynthetase syndrome. J Rheumatol 2010;37:1967.
38. Cavagna L, Prisco E, Montecucco C, Caporali R. Pulmonary arterial hypertension in antisynthetase syndrome: Comment on the article by Chatterjee and Farver (p 425-429). Arthritis Care Res 2011;63:633-4.
39. Tillie-Leblond I, Wislez M, Valeyre D, Crestani B, Rabbat A, Israel-Biet D, et al. Interstitial lung disease and anti-Jo-1 antibodies: Difference between acute and gradual onset. Thorax 2008;63:53-9.
40. Ingegnoli F, Lubatti C, Ingegnoli A, Boracchi P, Zeni S, Meroni PL. Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in anti-Jo1 antibody-positive polymyositis patients: A single centre study and review of the literature. Autoimmun Rev 2012;11:335-40.
41. Yamasaki Y, Yamada H, Nozaki T, Akaogi J, Nichols C, Lyons R, et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum 2006;54:2004-9.
42. Kalluri M, Sahn SA, Oddis CV, Gharib SL, Christopher-Stine L, Danoff SK, et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest 2009;135:1550-6.
43. Frank MB, McCubbin V, Trieu E, Wu Y, Isenberg DA, Targoff IN. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun 1999;12:137-42.
44. Schulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 2009;8:632-7.
45. Marie I, Hachulla E, Chérin P, Dominique S, Hatron PY, Hellot MF, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002;47:614-22.
46. Selva-O'Callaghan A, Labrador-Horrillo M, Muno-Gall X, Martinez-Gomez X, Majo-Masferrer J, Solans Laque R, et al. Polymyositis/dermatomyositis-associated lung disease: Analysis of a series of 81 patients. Lupus 2005;14:534-42.
47. Váncsa A, Csípo I, Németh J, Dévényi K, Gergely L, DankóK. Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int 2009;29:989-94.
48. Katsumata Y, Ridgway WM, Oriss T, Gu X, Chin D, Wu Y, et al. Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation. J Autoimmun 2007;29:174-86.
49. Baumann G, Zenke G, Wenger R, Hiestand P, Quesniaux V, Andersen E, et al. Molecular mechanisms of immunosuppression. J Autoimmun 1992;5 Suppl A:67-72.
50. Cho ML, Ju JH, Kim KW, Moon YM, Lee SY, Min SY, et al. Cyclosporine A inhibits IL-15-induced IL-17 production in CD4+ T cells via down-regulation of PI3K/Akt and NF-kappa B. Immunol Lett 2007;108:88-96.
51. Palkowitsch L, Marienfeld U, Brunner C, Eitelhuber A, Krappmann D, Marienfeld RB. The Ca2+-dependent phosphatase calcineurin controls the formation of the Carma1/Bcl10/Malt1 complex during T cell receptor induced NF-kappa B activation. J Biol Chem 2011;286:7522-34.
52. Pai S, Thomas R. Immune deficiency or hyperactivity - NF-kappa B illuminates autoimmunity. J Autoimmun 2008;31:245-51.
53. Creus KK, De Paepe BD, De Bleecker JLD. Idiopathic inflammatory myopathies and the classical NF-kB complex: Current insights and implications for therapy. Autoimmun Rev 2009;8:627-31.
54. Fujimoto H, D'Alessandro-Gabazza CN, Palanki MS, Erdman PE, Takagi T, Gabazza EC, et al. Inhibition of nuclear factor-kappa B in T cells suppresses lung fibrosis. Am J Respir Crit Care Med 2007;176:1251-60.
55. Kim WU, Cho ML, Kim SI, Yoo WH, Lee SS, Joo YS, et al. Divergent effect of cyclosporine on Th1/Th2 type cytokines in patients with severe, refractory rheumatoid arthritis. J Rheumatol 2000;27:324-31.
56. Szabo G, Gavala C, Mandrekar P. Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. J Invest Med 2001;49:442-9.
57. Cho ML, Kim WU, Min SY, Min DJ, Min JK, Lee SH, et al. Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor α?production by rheumatoid synoviocytes. Arthritis Rheum 2002;46:42-51.
58. Campelo SR, da Silva MB, Vieira JL, da Silva JP, Salgado CG. Effects of immunomodulatory drugs on TNF-alpha and IL-12 production by purified epidermal Langerhans cells and peritoneal macrophages. BMC Res Notes 2011;4:24.
59. Hassan AB, Fathi M, Dastmalchi M, Lundberg IE, Padyukov L. Genetically determined imbalance between serum levels of tumour necrosis factor (TNF) and interleukin (IL)-10 is associated with anti-Jo-1 and anti-Ro52 autoantibodies in patients with poly- and dermatomyositis. J Autoimmun 2006;27:62-8.